Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: A cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006;91:4769-75. (Pubitemid 44917305)
Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: A community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol 2010;72:377-82.
Gillam MP, Molitch ME, Lombardi G, et al. Advances in the treatment of prolactinomas. Endocr Rev 2006;27:485-534. (Pubitemid 44213229)
Schlechte JA. Clinical practice. Prolactinoma. N Engl J Med 2003;349:2035-41.
Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol 2006;65: 265-73. (Pubitemid 44079693)
Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary 2005;8:3-6. (Pubitemid 44680079)
Colao A, Sarno AD, Cappabianca P, et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 2003;148:325-31. (Pubitemid 36410718)
Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011;96:273-88.
Tamagno G, Daly AF, Deprez M, et al. Absence of hypogonadism in a male patient with a giant prolactinoma: A clinical paradox. Ann Endocrinol 2008;69:47- 52.
Sinha YN. Structural variants of prolactin: Occurrence and physiological significance. Endocr Rev 1995;16: 354-69.
Jackson RD, Wortsman J, Malarkey WB. Characterization of a large molecular weight prolactin in women with idiopathic hyperprolactinemia and normal menses. J Clin Endocrinol Metab 1985;61:258-64. (Pubitemid 15044257)
Shimatsu A, Hattori N. Macroprolactinemia: Diagnostic, clinical, and pathogenic significance. Clin Dev Immunol 2012;2012:167132.
Colao A. Pituitary tumours: The prolactinoma. Best Pract Res Clin Endocrinol Meta 2009;23:575-96.
Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocrinol Metab 1999;84:2518-22.
Nawar RN, AbdelMannan D, Selman WR, et al. Pituitary tumor apoplexy: A review. J Intensive Care Med 2008;23:75-90. (Pubitemid 351442753)
Laws ER. Pituitary tumor apoplexy: A review. J Intensive Care Med 2008;23:146-7. (Pubitemid 351442751)
Petrossians P, Borges-Martins L, Espinoza C, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005;152:61-6. (Pubitemid 40185454)
Pan L, Zhang N, Wang EM, et al. Gamma knife radiosurgery as a primary treatment for prolactinomas. J Neurosurg 2000;93(Suppl. 3):10-3. (Pubitemid 32799537)
Snyder PJ, Fowble BF, Schatz NJ, et al. Hypopituitarism following radiation therapy of pituitary adenomas. Am J Med 1986;81:457-62. (Pubitemid 16003868)
Barrande G, Pittino-Lungo M, Coste J, et al. Hormonal and metabolic effects of radiotherapy in acromegaly: Long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 2000;85:3779- 85.
Lancellotti P, Livadariu E, Markov M. Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 2008;159:1-5. (Pubitemid 351969123)
Wakil A, Rigby AS, Clark AL, et al. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 2008;159:R11-4.
Vallette S, Serri K, Rivera J, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 2009;12: 153-7.
Herring N, Szmigielski C, Becher H, et al. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol 2009;70:104-8.
Lafeber M, Stades AM, Valk GD, et al. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur J Endocrinol 2010;162:667-75.
Tan T, Cabrita IZ, Hensman D, et al., Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol 2010;73:369-74.
Elenkova A, Shabani R, Kalinov K, et al. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur J Endocrinol 2012;167:17- 25.
Steffensen C, Maegbaek ML, Laurberg P, et al. Heart valve disease among patients with hyperprolactinemia: A nationwide population-based cohort study. J Clin Endocrinol Metab 2012;97:1629-34.
Vroonen L, Jaffrain-Rea ML, Petrossians P, et al. Prolactinomas resistant to standard doses of cabergoline: A multicenter study of 92 patients. Eur J Endocrinol 2012;167:651-62.
Molitch ME. Pregnancy and the hyperprolactinemic woman. N Engl J Med 1985;312:1364-70. (Pubitemid 15118299)
Molitch ME. Prolactinoma in pregnancy. Best Pract Res Clin Endocrinol Metab 2011;25:885-96.
Petrossians P, de Herder W, Kwekkeboom D, et al. Malignant prolactinoma discovered by D2 receptor imaging. J Clin Endocrinol Metab 2000;85:398-401. (Pubitemid 32273169)
Raverot G, Castinetti F, Jouanneau E, et al. Pituitary carcinomas and aggressive pituitary tumours: Merits and pitfalls of temozolomide treatment. Clin Endocrinol 2012;76:769-75.
Colao A, Di Sarno A, Guerra E, et al. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol 2007;67: 426-33. (Pubitemid 47283843)
Dekkers OM, Lagro J, Burman P, et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: Systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:43-51.
Kharlip J, Salvatori R, Yenokyan G, Wand GS. Recurrence of hyperprolactinemia after withdrawal of longterm cabergoline therapy. J Clin Endocrinol Metab 2009; 94:2428-36.
Daly AF, Jaffrain-Rea ML, Ciccarelli A, et al. Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab 2006;91:3316-23. (Pubitemid 44402097)
Beckers A, Aaltonen LA, Daly AF, Karhu A. Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev 2013;34:239-77.
Vasilev V, Daly AF, Petrossians P, Zacharieva S, Beckers A. Familial pituitary tumor syndromes. Endocr Pract 2011;17(Suppl. 3):41-6.
